|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
SundayTeva Announces Copaxone(R) Reaches One Million Patient Years of Experience in the Treatment of Multiple Sclerosis
(Posted By: Josi Creek)
Approved in 1996, Copaxone(R) is the global market leader in the treatment of relapsing-remitting multiple sclerosis (RRMS) Ongoing, prospective, clinical trial follow-up reinforces the established efficacy and safety profile of Copaxone(R) in patients treated for more than 19 years Teva Pharmaceutical Industries, Ltd. /quotes/comstock/15*!teva/quotes/nls/teva (TEVA 63.20, +0.05, +0.08%) announced today that Copaxone(R) (glatiramer acetate injection), has now achieved one million patient years of experience in the treatment of relapsing-remitting multiple sclerosis (RRMS). This analysis is based on internal data submitted annually to the U.S. Food and Drug Administration (FDA). Click HERE to read the full story. |